User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Patient preferences for treatments to delay bone metastases.

Primary tabs

Hauber, A Brett Arellano, Jorge Qian, Yi González, Juan Marcos Posner, Joshua D Tombal, Bertrand [UCL] Body, Jean-Jacques

Most patients with advanced prostate cancer (PCa) develop bone metastases (BM) and present with bone complications like fracture. Bone-targeted agents that prevent metastasis-induced bone complications can cause adverse events. Understanding how patients view treatment options may optimize care. This study aimed to quantify how PCa patients value a hypothetical treatment that delays BM but can cause osteonecrosis of the jaw (ONJ). The study also assessed the value patients place on avoiding metastasis-induced bone complications versus increased survival.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "The Prostate" - Vol. 74, no.15, p. 1488-1497 (2014)
Peer reviewed yes
Publisher JohnWiley & Sons, Inc. ((United States) Hoboken)
issn 0270-4137
e-issn 1097-0045
Publication status Publié
Affiliations UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - (SLuc) Service d'urologie
Keywords bone pain ; discrete-choice experiment ; osteonecrosis of the jaw (ONJ) ; prostate cancer ; skeletal-related events (SREs) ; time tradeoff
Links
  1. Ferlay, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] (2013)
  2. Amaral Teresa Maria Santos, Macedo Daniela, Fernandes Isabel, Costa Luis, Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment, 10.1155/2012/327253
  3. Sharifi Nima, Androgen Deprivation Therapy for Prostate Cancer, 10.1001/jama.294.2.238
  4. Clines Gregory A., Guise Theresa A., Molecular mechanisms and treatment of bone metastasis, 10.1017/s1462399408000616
  5. Lamothe, J Natl Med Assoc, 78, 1083 (1986)
  6. Bubendorf Lukas, Schöpfer Alain, Wagner Urs, Sauter Guido, Moch Holger, Willi Niels, Gasser Thomas C., Mihatsch Michael J., Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients, 10.1053/hp.2000.6698
  7. Nelson Joel B., Love William, Chin Joseph L., Saad Fred, Schulman Claude C., Sleep Darryl J., Qian Jiang, Steinberg Joyce, Carducci Michael, , Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer, 10.1002/cncr.23864
  8. Sartor O., Eisenberger M., Kattan M. W., Tombal B., Lecouvet F., Unmet Needs in the Prediction and Detection of Metastases in Prostate Cancer, 10.1634/theoncologist.2013-0027
  9. Fizazi Karim, Carducci Michael, Smith Matthew, Damião Ronaldo, Brown Janet, Karsh Lawrence, Milecki Piotr, Shore Neal, Rader Michael, Wang Huei, Jiang Qi, Tadros Sylvia, Dansey Roger, Goessl Carsten, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, 10.1016/s0140-6736(10)62344-6
  10. Hoffman-Censits Jean, Fu Maofu, Chemotherapy and Targeted Therapies: Are We Making Progress in Castrate-Resistant Prostate Cancer?, 10.1053/j.seminoncol.2013.04.015
  11. MacVicar, Curr Opin Oncol, 25, 252 (2013)
  12. Smith Matthew R, Saad Fred, Coleman Robert, Shore Neal, Fizazi Karim, Tombal Bertrand, Miller Kurt, Sieber Paul, Karsh Lawrence, Damião Ronaldo, Tammela Teuvo L, Egerdie Blair, Van Poppel Hendrik, Chin Joseph, Morote Juan, Gómez-Veiga Francisco, Borkowski Tomasz, Ye Zhishen, Kupic Amy, Dansey Roger, Goessl Carsten, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, 10.1016/s0140-6736(11)61226-9
  13. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm235829.htm
  14. de Bekker-Grob E W, Bliemer M C J, Donkers B, Essink-Bot M-L, Korfage I J, Roobol M J, Bangma C H, Steyerberg E W, Patients’ and urologists’ preferences for prostate cancer treatment: a discrete choice experiment, 10.1038/bjc.2013.370
  15. Marshall Deborah, Bridges John F.P., Hauber Brett, Cameron Ruthanne, Donnalley Lauren, Fyie Ken, Johnson F. Reed, Conjoint Analysis Applications in Health – How are Studies being Designed and Reported? : An Update on Current Practice in the Published Literature between 2005 and 2008, 10.2165/11539650-000000000-00000
  16. Bridges John F.P., Hauber A. Brett, Marshall Deborah, Lloyd Andrew, Prosser Lisa A., Regier Dean A., Johnson F. Reed, Mauskopf Josephine, Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force, 10.1016/j.jval.2010.11.013
  17. Blinman P., King M., Norman R., Viney R., Stockler M. R., Preferences for cancer treatments: an overview of methods and applications in oncology, 10.1093/annonc/mdr559
  18. Hauber A.B., Arden N.K., Mohamed A.F., Johnson F.R., Peloso P.M., Watson D.J., Mavros P., Gammaitoni A., Sen S.S., Taylor S.D., A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis, 10.1016/j.joca.2012.11.007
  19. Mohamed Ateesha F., Hauber A. Brett, Neary Maureen P., Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma : , 10.2165/11593370-000000000-00000
  20. Marta-Pedroso Cristina, Freitas Helena, Domingos Tiago, Testing for the survey mode effect on contingent valuation data quality: A case study of web based versus in-person interviews, 10.1016/j.ecolecon.2007.02.005
  21. Nielsen Jytte Seested, Use of the Internet for willingness-to-pay surveys, 10.1016/j.reseneeco.2010.01.006
  22. Orme, Getting started with conjoint analysis: strategies for product design and pricing research (2006)
  23. Reed Johnson F., Lancsar Emily, Marshall Deborah, Kilambi Vikram, Mühlbacher Axel, Regier Dean A., Bresnahan Brian W., Kanninen Barbara, Bridges John F.P., Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force, 10.1016/j.jval.2012.08.2223
  24. Smith Matthew R., Saad Fred, Oudard Stephane, Shore Neal, Fizazi Karim, Sieber Paul, Tombal Bertrand, Damiao Ronaldo, Marx Gavin, Miller Kurt, Van Veldhuizen Peter, Morote Juan, Ye Zhishen, Dansey Roger, Goessl Carsten, Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time, 10.1200/jco.2012.44.6716
  25. El-Amm Joelle, Freeman Ashley, Patel Nihar, Aragon-Ching Jeanny B., Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms, 10.1155/2013/210686
  26. Lipton Allan, Balakumaran Arun, Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors, 10.1586/ecp.12.35
Bibliographic reference Hauber, A Brett ; Arellano, Jorge ; Qian, Yi ; González, Juan Marcos ; Posner, Joshua D ; et. al. Patient preferences for treatments to delay bone metastases.. In: The Prostate, Vol. 74, no.15, p. 1488-1497 (2014)
Permanent URL http://hdl.handle.net/2078.1/151777